Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MMP13 | P45452 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 4/20 | 0.34 |
| ▸ | MMP8 | P22894 | 4/20 | 0.34 |
| ▸ | CASR | P41180 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797087 | 1.00 | MMP2 (0.49) | MMP2MMP13ALDH1A1BMP1MMP3 | |
| SCHEMBL6806356 | 0.94 | MMP2 (0.53) | MMP2MMP13BMP1MMP3MMP9 | |
| SCHEMBL6797426 | 0.93 | MMP2 (0.49) | MMP2MMP13ALDH1A1BMP1MMP3 | |
| SCHEMBL6797425 | 0.93 | MMP2 (0.49) | MMP2MMP13ALDH1A1BMP1MMP3 | |
| SCHEMBL6797057 | 0.85 | MMP2 (0.67) | MMP2MMP13BMP1MMP3MMP9 | |
| SCHEMBL6797054 | 0.85 | MMP2 (0.67) | MMP2MMP13BMP1MMP3MMP9 | |
| SCHEMBL6797089 | 0.85 | BMP1 (0.40) | MMP2MMP13ALDH1A1BMP1MMP3 | |
| SCHEMBL6797432 | 0.83 | MMP2 (0.56) | MMP2MMP13ALDH1A1BMP1MMP3 | |
| SCHEMBL6865426 | 0.81 | L3MBTL1 (0.35) | ALDH1A1TSHRHSD17B10L3MBTL1MEN1 | |
| SCHEMBL6796522 | 0.77 | MMP2 (0.68) | MMP2MMP13BMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977745-B1 | THIOARYL SULFONAMIDE HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | PHARMACIA CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-6087359-A | A MATRIX METALLOPROTEASE ENZYME INHIBITOR | PHARMACIA CORPORATION | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034071-A1 | Thioaryl sulfonamide hydroxamic acid compounds | MMP10, MMP1, MMP3 | MMP2 4/4885MMP13 11/4885ALDH1A1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.